Clinical Trials Browser

Phase 1/2 × anlotinib × 1 year × Clear all

NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Phase 1/2 Recruiting

Craniopharyngioma

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms